Project Grant R01AI203702

The National Institute of Allergy and Infectious Diseases awarded $1.744 million to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the MAATCH project—Modeling Antibody Approaches for a Tailored Cure for HIV.

The award funds laboratory-based experiments and mathematical modeling to determine the degree of personalization required to advance antibody-based HIV interventions, including B cell vaccines and broadly neutralizing antibody infusions, toward inducing HIV remission. Under Aim 1, the recipient will model, design, test, and compare three levels of vaccine personalization: fully personalized designs matching autologous virus, semi-personalized designs with artificial intelligence optimization, and clade-centralized designs based on subtype consensus. Under Aim 2, the recipient will develop an in-silico tool for predicting HIV-1 envelope sensitivity to specific broadly neutralizing antibodies to enable tailored antibody regimen selection. The work will leverage samples from four completed and one ongoing immunotherapy clinical trial involving participants representing HIV subtypes B and CRF01_AE, with documented virological outcomes following analytical treatment interruption.

The recipient is headquartered in Bethesda, Maryland, with place of performance in Westlake, Maryland. The period of performance runs from September 1, 2026, through August 31, 2031. The grant obligates $1.744 million under the Project Grant assistance type.